Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy
- 7 December 2020
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 40 (5) , 885-898
Abstract
Recently, immune checkpoint blockade (ICB), especially anti-programmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an increasingly appealing therapeutic strategy for cancer patients. However, only a small portion of patients responds to anti-PD treatment. Therefore, treatment strategies are urgently needed to reverse the ICB-resistant tumor microenvironment (TME). It has become clear that the TME has diminished innate sensing that is critical to activate adaptive immunity. In addition, tumor cells upregulate various immunosuppressive factors to diminish the immune response and resist immunotherapy. In this review, we briefly update the current small molecular drugs that could synergize with immunotherapy, especially anti-PD therapy. We will discuss the modes of action by those drugs including inducing innate sensing and limiting immunosuppressive factors in the TME.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RR150072)
This publication has 90 references indexed in Scilit:
- MerTK inhibition in tumor leukocytes decreases tumor growth and metastasisJournal of Clinical Investigation, 2013
- Regulation of COX2 Expression in Mouse Mammary Tumor Cells Controls Bone Metastasis and PGE2-Induction of Regulatory T Cell MigrationPLOS ONE, 2012
- A Live Imaging Cell Motility Screen Identifies Prostaglandin E2 as a T Cell Stop Signal AntagonistThe Journal of Immunology, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T CellsThe Journal of Immunology, 2010
- Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell–like and Foxp3+ regulatory T cellsNature Immunology, 2010
- Deoxycholate induces COX-2 expression via Erk1/2-, p38-MAPK and AP-1-dependent mechanisms in esophageal cancer cellsBMC Cancer, 2009
- Immunobiology of the TAM receptorsNature Reviews Immunology, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- A survey of telomerase activity in human cancerEuropean Journal of Cancer, 1997